The
biosynthesis of myo-inositol (mI) is central
to the function of many organisms across all kingdoms of life. The
first and rate-limiting step in this pathway is catalyzed by 1l-myo-inositol 1-phosphate synthase (mIPS),
which converts d-glucose 6-phosphate (G6P) into 1l-myo-inositol 1-phosphate (mI1P). Extensive studies
have shown that this reaction occurs through a stepwise NAD+-dependent redox aldol cyclization mechanism producing enantiomerically
pure mI1P. Although the stereochemical nature of the mechanism has
been elucidated, there is a lack of understanding of the importance
of amino acid residues in the active site. Crystal structures of mIPS
in the ternary complex with substrate analogues and NAD(H) show different
ligand orientations. We therefore proposed to use isosteric and isoelectronic
analogues of G6P to probe the active site. Here, we report the synthesis
of the methylenephosphonate, difluoromethylenephosphonate, and (R)- and (S)-monofluoromethylenephosphonate
analogues of G6P and their evaluation as inhibitors of mIPS activity.
While the CH2 and CF2 analogues were produced
with slight modification of a previously described route, the CHF
analogues were synthesized through a new, shorter pathway. Kinetic
behavior shows that all compounds are reversible competitive inhibitors
with respect to G6P, with K
i values in
the order CF2 (0.18 mM) < (S)-CHF (0.24
mM) < (R)-CHF (0.59 mM) < CH2 (1.2
mM). Docking studies of these phosphonates using published crystal
structures show that substitution of the oxygen atom of the substrate
changes the conformation of the resulting inhibitors, altering the
position of carbon-6 and carbon-5, and this change is more pronounced
with fluorine substitution.